Mazdutide

GLP-1 / glucagon dual agonist · metabolic research peptide (IBI362 / LY3305677)

≥ 99.0% · target, verify batch COACAS 2259884-03-0RUO

Research statusDefined peptide with phase 1-3 evidence. China's NMPA approved named finished formulations for chronic weight management in June 2025 and type 2 diabetes glycemic control in September 2025; it is not FDA-approved in the United States. reference context · supplied material is RUO

Supplied formTritriacontapeptide (linear, 33-residue oxyntomodulin/GLP-1-glucagon dual-agonist analog, lipidated — C20 fatty-diacid conjugation at Lys20 via gammaGlu-AEEA-AEEA linker)

Lead time14–21 days

Mazdutide — Lot-specific lyophilized research peptide; confirm released-lot appearance on the COA

Mazdutide — Lot-specific lyophilized research peptide; confirm released-lot appearance on the COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research value includes GLP-1R/GCGR dual-receptor pharmacology, structure-activity and energy-expenditure models, lipidated-peptide analytical methods, formulation and albumin-binding studies, and comparison with other incretin multi-agonist standards
These are not weight-loss, glycemic or liver-fat benefit claims for this product.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 2259884-03-0
Formula: C₂₀₇H₃₁₇N₄₅O₆₅ (PubChem CID 167312357 reference structure; confirm the supplied form on the batch COA)
Molecular weight: approximately 4476.0 g/mol
Appearance: Lot-specific lyophilized research peptide; confirm released-lot appearance on the COA
Purity: ≥ 99.0% · target, verify batch COA
Storage: Follow the released-lot label and stability statement. Keep lyophilized material sealed and protected from moisture and light as specified. Qualify solvent, pH, concentration, container, temperature and hold time after reconstitution; do not infer a universal cold-chain or frozen shelf life.
MOQ: On request
Lead time: 14–21 days

PubChem CID 167312357

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Mazdutide

Mazdutide is an oxyntomodulin-related synthetic peptide designed to activate GLP-1 and glucagon receptors and bearing a long-chain fatty-diacid albumin-binding modification. Its exact published structure representation is not fully consistent across public databases, making lot-level sequence, linker and mass documentation essential.

GLP-1R/GCGR dual signaling; receptor pharmacology and structure-activity work; lipidated-peptide identity and impurity methods; albumin-binding, formulation and stability research; controlled comparison with survodutide, tirzepatide or retatrutide reference standards.

Mechanism context

The question the literature is testing

Mazdutide activates GLP-1R and GCGR in assay- and species-dependent systems. GLP-1R/GCGR dual agonism is studied as a combination of appetite, glycemic and energy-expenditure pathways, while lipidation supports albumin association in drug development. Vendor Ki values are not treated as universal potency constants.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaMetabolic and incretin research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Research Use Only; not a sterile finished drug and not for human or veterinary use
Adverse events and contraindications from clinical studies or a jurisdiction-specific label describe the tested finished formulation, not this lot
Handle under the SDS and institutional risk assessment.

Interactions reported in the literature

For bench studies, control receptor expression, glucose, albumin or serum content, assay timing and comparator concentration
No clinical combination with insulin, semaglutide, metformin, GH-axis peptides or other products is recommended.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Mazdutide factory batch COAs

Mazdutide 5 mg Factory batch COA protected preview

Mazdutide5 mg · WHJLP-MAZ5-260327-D

Mazdutide 10 mg Factory batch COA protected preview

Mazdutide10 mg · WHJLP-MAZ10-260327-D

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require exact sequence, termini, non-natural residues, lipidation site and linker identity, RP-HPLC purity with method, intact mass, LC-MS/MS modification evidence, peptide content, related substances, counterion, water and residual solvents
Appearance or clear reconstitution cannot establish identity, endotoxin, sterility or suitability.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

MAZ-05MG5 mg10 vials

MAZ-10MG10 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot label and stability statement. Keep lyophilized material sealed and protected from moisture and light as specified. Qualify solvent, pH, concentration, container, temperature and hold time after reconstitution; do not infer a universal cold-chain or frozen shelf life.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity and nomenclature: PubChem CID 167312357 and IUPHAR/BPS ligand 13924. Formula discrepancy cross-check: KEGG D12225 and FDA GSRS. Clinical evidence context: GLORY and DREAMS primary reports. China approval chronology is supported by Innovent’s June and September 2025 notices; sponsor claims are not transferred to this RUO lot. A March 2026 FDA warning letter expressly treated mazdutide products marketed by the cited US vendor as unapproved new drugs, supporting the US boundary without implying that the warning letter evaluates this lot.

01
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
New England Journal of Medicine · 2025 · peer-reviewed original research (phase 3 randomized controlled trial, GLORY-1)
Open source
02
Mazdutide versus placebo in Chinese adults with type 2 diabetes
Nature · 2026 · peer-reviewed original research (phase 3 randomized controlled trial, DREAMS-1)
Open source
03
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
Nature · 2026 · peer-reviewed original research (phase 3 active-comparator randomized controlled trial, DREAMS-2)
Open source
04
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
Nature Communications · 2023 · peer-reviewed original research (phase 2 randomized controlled trial)
Open source
05
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
eClinicalMedicine (The Lancet Discovery Science) · 2022 · peer-reviewed original research (phase 1b randomized controlled trial)
Open source
06
Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials
Diabetes, Obesity and Metabolism · 2026 · peer-reviewed systematic review / meta-analysis
Open source
07
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Diabetes (American Diabetes Association) · 2009 · peer-reviewed original research (foundational preclinical study)
Open source
08
What is the pipeline for future medications for obesity?
International Journal of Obesity · 2025 · peer-reviewed narrative review (independent expert commentary including mazdutide)
Open source

Product FAQ

Questions buyers ask about Mazdutide

Where does Mazdutide sit in the incretin receptor-coverage series?+

Receptor coverage distinguishes the named molecules: tirzepatide targets GIPR + GLP-1R, mazdutide targets GLP-1R + GCGR, and retatrutide targets GIPR + GLP-1R + GCGR. This is a classification, not proof of matched potency, signaling bias, exposure or efficacy. A comparison must verify each lot's exact identity and use matched receptor expression, molar concentration, albumin or serum conditions and assay timing.

Why must Mazdutide identity be verified per COA?+

CAS 2259884-03-0 is linked to mazdutide by PubChem and IUPHAR/BPS, but public formula and structure records conflict. The COA should therefore state the full modified sequence, lipidation site and linker, counterion, theoretical mass and observed intact mass. A regulatory approval for a named finished formulation does not resolve the identity of a separate research lot.

Should a lab source Mazdutide or Survodutide for GLP-1 / glucagon dual-agonist work?+

Both are designed for GLP-1R + GCGR agonism without a GIPR arm, but they have different sequences, lipidation chemistry and receptor-pharmacology profiles. The choice is therefore both mechanistic and documentary: align the reference material to the molecule and evidence set being studied, qualify exact identity per batch COA and do not treat them as interchangeable controls.

Mazdutide

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Mazdutide

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Mazdutide factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight

Mazdutide versus placebo in Chinese adults with type 2 diabetes

Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

What is the pipeline for future medications for obesity?

Questions buyers ask about Mazdutide

Compare adjacent molecules and documentation needs.

Survodutide

Retatrutide

Tirzepatide

Semaglutide